Protein ubiquitination is important for cell signaling, DNA repair and proteasomal degradation, and it is not surprising that alterations in ubiquitination occur frequently in cancer. Ubiquitin conjugating enzymes (E2s) mediate ubiquitination by selective interactions with ubiquitin activating (E1) and ubiquitin ligase (E3) enzymes, and thus selective E2 small molecule inhibitor (SMIs) will provide specificity unattainable with proteasome inhibitors. Here we describe synthesis and functional characterization of the first SMIs of human E2 Rad6B, a fundamental component of translesion synthesis DNA repair. A pharmacophore model for consensus E2-ubiquitin binding sites was generated for virtual screening to identify E2 inhibitor candidates. 12 triazine (TZ) analogs screened in silico by molecular docking to the Rad6B X-ray structure were verified by their effect on Rad6B ubiquitination of histone H2A. TZs#8 and 9 docked to the Rad6B catalytic site with highest complementarity. TZs#1, 2, 8 and 9 inhibited Rad6B-ubiquitin thioester formation and subsequent ubiquitin transfer to histone H2A. SMI#9 inhibition of Rad6 was selective as BCA2 ubiquitination by E2 UbcH5 was unaffected by SMI#9. SMI#9 more potently inhibited proliferation, colony formation and migration than SMI#8, and induced MDA-MB-231 breast cancer cell G2/M arrest and apoptosis. Ubiquitination assays using Rad6 immunoprecipitated from SMI#8 or 9 treated cells confirmed inhibition of endogenous Rad6 activity. Consistent with our previous data showing Rad6B-mediated polyubiquitination stabilizes β-catenin, MDA-MB-231 treatment with SMIs#8 or 9 decreased β-catenin protein levels. Together these results describe identification of the first Rad6 SMIs.
Introduction
Protein ubiquitination involves the activities of an ubiquitin activating enzyme (E1) that initiates ubiquitination by forming an ATP-dependent thioester bond between its active site cysteine and the ubiquitin carboxyl terminus. The activated ubiquitin is transferred to an ubiquitin conjugating enzyme (E2) with resultant formation of a thioester linked E2-ubiquitin complex, and subsequently transferred to substrate directly or via interaction with an ubiquitin-protein ligase (E3), leading to substrate mono-or polyubiquitination. E2s play a central role in ubiquitin transfer, as they are responsible both for E3 selection and substrate modification. Recent work demonstrates E2s are important for dictating the final ubiquitinated product, i.e., a mono-or polyubiquitinated chain of a specific lysine linkage (1) (2) (3) , and ultimately the fate of the substrate:
proteasomal degradation or signaling.
Rad6, the first cloned E2 (4) , is essential for postreplication DNA repair. Yeast rad6 mutants lacking the active site cysteine exhibit DNA damaging agent sensitivity, UV-induced mutagenesis defects (5) , impaired proteolysis by the N-end rule pathway (6, 7) , and cell cycle arrest (8) , implicating Rad6 ubiquitin conjugating activity as necessary for its many functions.
The yeast Rad6 human homologues, HHR6A and HHR6B (or Rad6A and Rad6B), encode ubiquitin conjugating enzymes and complement DNA repair and UV mutagenesis defects of S. cerevisiae mutant rad6 (9, 10) . The requirement for at least one functional Rad6A or Rad6B allele in all somatic cell types is confirmed by the nonviability of mice lacking both Rad6A and Rad6B homologues (11) . By differential display gene expression analysis we identified Rad6B overexpression in mouse and human breast cancer lines and tumors. Constitutive Rad6B overexpression in nontransformed human breast cells induces multinucleated cell formation, centrosome amplification, abnormal mitosis, aneuploidy, and transformation (12) ubiquitinates histones in the absence of E3 proteins (4, 13) . Similarly, Rad6B ubiquitinates β-catenin in vitro in the absence of E3 ligases, and the K63-linked ubiquitinated β-catenin conjugates generated by Rad6B are insensitive to 26S proteasome (14) , indicating Rad6B is important for β-catenin stabilization/activation in breast cancer (14, 15) . Rad6 and its E3 ligase partner Rad18 mediate PCNA mono-and K63-linked polyubiquitination (16, 17) . These data suggest Rad6 is important for genomic integrity maintenance via its ubiquitin conjugating activity, and that imbalances in its levels/activity could contribute to genomic instability via error-prone DNA repair and/or ubiquitination of substrates with resultant altered signaling or proteasomal processing.
We report here synthesis, identification and functional characterization of the first known Rad6B small molecule inhibitors (SMIs). These SMIs dock to the Rad6B catalytic site, inhibit Rad6B-induced histone H2A ubiquitination, downregulate intracellular β-catenin, induce G2/M arrest and apoptosis, and inhibit proliferation and migration of metastatic human breast cancer cells.
Materials and methods
Pharmacophore model for virtual screening. Identification of new potential lead compounds with E2 inhibitory activity was based on computational modeling using MOE 2010.10 (Molecular Operating Environment, Chemical Computing Group Inc., Montreal), described in detail elsewhere (18) . Briefly, an E2-ubiquitin consensus-binding site was built based on the NMR structure of ubiquitin conjugating enzyme Ubc1-ubiquitin complex (19 donor and H-acceptor points, and was refined by including excluded volumes around these points. Virtual screening of the pharmacophore model against the ZINC database (pre-prepared using drug-like filters) identified the substituted diamino-triazine (TZ) core structure that formed the starting point for analog synthesis.
Experimental Chemistry. Melting points were measured on a Griffin apparatus and are uncorrected. Mass spectra were recorded on a Bruker MicroTOF instrument or at the EPSRC National Mass Spectrometry Centre (Swansea, U.K.). NMR spectra were recorded on a Bruker AVANCE 500 MHz instrument. Merck silica gel 60 was used for column chromatography.
Following purification, all TZ compounds were determined to possess 95% purity as determined by spectroscopic and combustion analyses (±0.4% CHN tested in duplicate).
TZ compound synthesis. The TZ compounds synthesis scheme ( Fig. 1 ) involved three steps using commercially available starting materials.
Step 1 involved arylbiguanide synthesis (3a-f; (20) ).
Step 2 involved (4-amino-6-(phenylamino)- [1, 3, 5] triazin-2-ylmethanol synthesis (5a-f; (21)).
Step 3 involved synthesis of (4-amino-6-(phenylamino)- [1, 3, 5] triazin-2-ylmethyl benzoate, which yielded TZs #1-11. TZ#13 (4-amino-6-(2-ethylphenylamino)- [1, 3, 5] triazin-2-yl)methyl 4-hydroxybenzoate) was synthesized from TZ#6 ( Fig. 1) . Details of chemical synthesis, purification, and NMR and MassSpec data of TZ compounds are shown in Supplementary Data.
Rad6 nomenclature.
We previously demonstrated that the Rad6B gene is overexpressed in breast cancer by transcript sequencing and Rad6B-specific shRNA transfections (12, 14) .
However, since the peptide we used for Rad6B antibody generation is 91% conserved in human Ubiquitin conjugating activity assay. Histone H2A ubiquitination assays were performed at room temperature for 1 h with histone H2A (2.5 μg; Roche Biotech), ubiquitin activating enzyme E1 (50 μg/ml, BioMol), recombinant human Rad6B (85 μg/ml), ubiquitin (1.25 mg/ml; Roche), 2 mM MgCl 2 , 4 mM ATP and energy regeneration system (Boston Biochem) in reaction buffer (50 mM Tris-HCl, pH 7.5) (14) . To assess TZ compound effects on Rad6B-mediated ubiquitination, reactions containing Rad6B were preincubated with the compounds (25 nM) or vehicle for 1 h prior to adding ubiquitin and histone H2A. Chemotaxis assay. Chemotaxis assays were performed in Boyden chambers containing 8 μm pore-size polycarbonate membrane. MDA-MB-231 cells were incubated with vehicle, 25 μM of TZs, or 1-100 μM of SMIs#8 or 9 for 1 h at 37 o C and 5% CO 2. Cells were rinsed with serumfree media and 50x10 3 cells were placed in the upper chamber, and 100 μl of serum-free medium containing 100 μg/ml Matrigel (BD Biosciences) was placed in the lower chamber. Cells were incubated for 6 h at 37 o C and 5% CO 2 , and migrated cells were fixed, stained with Protocol Hema 3 stain set (Fisher Scientific), and quantitated with NIH Image Version 1.62. Assays were performed in triplicate.
Molecular docking.
To assess interactions between TZs and Rad6B, molecular docking was carried out using PyMol software. The human Rad6B protein X-ray structure (2YB6) was used to estimate binding affinities and TZ compound orientation to the Rad6B active site (24) . The average RMSD between X-ray (2YB6) (24) and NMR (2Y4W) (25) structures is 2.054, and the RMSD at the active site is 1.918. Analogs showing minimum docking score and binding energy were identified as they are predicted to bind favorably to Rad6B. TZ compound synthesis. Target TZ compounds were synthesized in three steps (Fig. 1) .
Results
Reaction of the appropriate (substituted) aniline (1a-f) with dicyandiamide (2) under acidic conditions produced the corresponding biguanide (3a-f) as the hydrochloride salt (46-84 % yield) that was used in the next step without further purification. Condensation of the biguanide with ethyl glycolate (4) in a solution of sodium ethoxide in ethanol gave rise to a mixture of products from which the required (4-amino-6-(phenylamino)- [1, 3, 5] triazin-2-yl)methanol (5a-f) was purified by column chromatography (14-37% yield). Compound 5a (TZ#15; R=H) was retained for anticancer evaluation. Esterification of the (4-amino-6-(phenylamino)- [1, 3, 5] triazin-2-yl)methanol compounds using substituted benzoyl chlorides gave the final TZs #1-11 following column chromatography (45-85% yield). Product TZ#6, containing the benzyloxy protecting group, was deprotected by hydrogenation to yield TZ#13 (33% yield). TZs#4, 12, and 14 are missing due to failed synthesis or very low quantitites/impure products.
Identification of SMI analogs with Rad6B inhibitory activity. TZs with Rad6B inhibitory activity were identified by in vitro ubiquitination assays with recombinant human Rad6B and histone H2A in the presence of TZ compounds. Since histones H2A and H2B are Rad6A and Rad6B ubiquitination targets (26), they are ideal substrates for screening compounds with Rad6 inhibitory activity. Inhibition of Rad6 ubiquitin conjugating activity was evaluated by effects on Rad6B-ubiquitin thioester formation (Rad6B~Ub) and ubiquitin transfer to histone H2A (Ub-H2A). In control reactions, strong ubiquitination of histone H2A was observed. Rad6B-ubiquitin thioester levels, however, were negligible, suggesting robust ubiquitin transfer to substrate.
Reactions including TZs#1, 2, 8 or 9 ( Fig. 2A) showed reduced Rad6B-ubiquitin thioester formation and ~35-50% decrease in histone H2A ubiquitination compared to control ( Fig. 2A) .
These data suggest inhibition of substrate ubiquitination potentially resulted from these compounds interfering with Rad6B-ubiquitin thioester formation. TZs#3 and 5 caused modest inhibition (~30%), while TZs#6, 7, 10, 11, 13, and 15 may be considered as Rad6B activators as strong bands corresponding to both Rad6B-ubiquitin thioester and ubiquitinated histone H2A were detectable (Fig. 2A) . Specificity of SMI#9 for Rad6B was tested in ubiquitination assays using recombinant human UbcH5 (an E2 sharing 37% identity with Rad6B), SMI#9, and UbcH5 ubiquitination substrate BCA2 E3 ligase (23) . The robust ubiquitination of BCA2 by UbcH5 was unaffected by Rad6B SMI#9 (Fig. 2B) . Further, Rad6B E2 activity does not substitute for UbcH5 in BCA2 ubiquitination, verifying the selectivity of Rad6B and SMI#9 (Fig. 2B ).
Molecular Docking to Rad6B. In silico molecular docking analysis of intermolecular interactions between TZs and Rad6B indicated SMIs#8 and 9 have the highest geometric shape complementarity scores. Based on the Rad6B X-ray structure, the Rad6B active site topology suggests SMIs#8 and 9 form noncovalent interactions with Thr69 (in β4 region of Rad6B), Asp90 and Glu93 (adjacent to the Rad6B catalytic site Cys), and Asn119 and Ala122 (in the connecting region between helices α2 and α3) (Fig. 2C-E) . The validity of these predictions is consistent with our experimental data showing TZs#8 and 9 possess Rad6B ubiquitin conjugation inhibitory activity ( Fig. 2A) . Consistent with noncomplementary activities of Rad6B and UbcH5 in BCA2 ubiquitination (Fig. 2B) , UbcH5 shares only one (Asp90) of five noncovalent interaction sites proposed for SMIs#8 and 9 interaction with Rad6B.
Rad6B SMI#9 inhibits MDA-MB-231 cell proliferation and migration. Effects of Rad6B
inhibitors on nontransformed MCF10A and metastatic MDA-MB-231 cell proliferation were examined. MCF10A cells express low Rad6B levels unless exposed to DNA damaging agents whereas MDA-MB-231 cells overexpress Rad6B (12) . Among the TZs tested (#1, 2, 8, 9 and 15), only SMIs#8 and 9 inhibited MDA-MB-231 cell proliferation (Fig. 3A and data not shown) . 
SMI#9 inhibited MDA-MB-231 cell proliferation more robustly (IC50 ~6 μM) than its structurally related SMI#8 analog (IC 50 ~25 μM; Fig. 3A) . The reduced inhibitory activity of SMI#8 compared to SMI#9 appears to result from poor solubility of SMI#8 as traces of precipitation began appearing at 10 μM concentration. The bulk of MDA-MB-231 cells treated with >10 μM SMI#9 displayed a round morphology compared to controls and <5 μM doses of SMI#9, whereas treatment with up to 50 μM SMI#8 did not produce pronounced morphological changes of surviving cells compared to control ( Figure 3B and data not shown). MCF10A cell proliferation was unaffected by SMIs#8 and 9 (Fig. 3C) . (Fig. 3D bottom panel) .
Effect of Rad6 inhibitors on cell survival. Since MTT assays (Fig. 3A) showed growth inhibitory effects with SMIs#8 and 9, we tested whether inhibition resulted from a cytostatic or cytotoxic response. Cells undergoing apoptosis/necrosis were detected by differential uptake of the fluorescent DNA binding dyes acridine orange and ethidium bromide. Consistent with MTT data (Fig. 3A) , 5 μM SMI#9 treatment triggered morphological changes consistent with apoptosis in a time-dependent manner. Early apoptosis marked by intercalated acridine orange within fragmented DNA (22) 4A). Vehicle or 10 μM TZ#15 treated cells were unaffected as >98% showed a green intact nuclear structure. A small proportion of SMI#8 treated cells exhibited nuclear ethidium bromide staining (~8.5%), whereas most showed extranuclear ethidium bromide staining (Fig. 4A) .
Clonogenic assays were performed to determine whether SMIs#8 and 9 compromised cell reproductive capacity. Colony forming efficiencies of MDA-MB-231 cells treated with SMIs#8 or 9 were 44.4 and 3.7 %, respectively, of vehicle controls (Fig. 4C) . Colonies formed from SMI#9 treated cells appeared to also be defective in migration as dividing cells were longdrawn-out and not completely physically separated (Fig. 4B , compare magnified images of colonies from vehicle and SMI#9). 13 72 h). These data are consistent with MTT assays (Fig. 3A) , and agree with our previous data showing maximal Rad6 expression in late S/G2 phase which decreases as cells reenter G1 (27) . levels in MDA-MB-231 cells were unaffected by these compounds, suggesting SMIs#8 and 9 possess Rad6 inhibitory activity but have little effect on Rad6 protein steady-state levels (Fig.   5C , bottom panel). Consistent with SMI#9 inhibition of MDA-MB-231 cell proliferation (Fig.   3A) , PCNA protein levels were decreased in SMI#9 treated cells compared to vehicle or SMI#8 treated cells (Fig. 5C, bottom panel) . SMI#8 and 9 downregulate β-catenin. We previously demonstrated Rad6B stabilizes β-catenin by K63-linked polyubiquitination that protects it from 26S proteasomal degradation (14) . To assess SMIs#8 and 9 effects on β-catenin protein levels, immunoblot analysis was performed on MDA-MB-231 cells treated with various SMIs#8 or 9 doses. Both compounds decreased high molecular weight polyubiquitinated (14) and nascent β-catenin protein levels in a dose dependent manner compared to vehicle (Fig. 5D, right panel) . The β-catenin protein level decrease was verified by immunofluorescence staining of Rad6 and β-catenin. Whereas control MDA-MB-231 cells showed strong Rad6 and β-catenin staining colocalizing to perinuclear compartments, SMIs#8 or 9 treatments dramatically reduced β-catenin staining as visualized by reduced merged Rad6/β-catenin yellow fluorescence (Fig. 5D, left panel) . Consistent with immunoblotting data in Fig. 5C , SMIs#8 and 9 minimally affected Rad6 staining. These data show that decreased β-catenin levels caused by SMIs#8 and 9 are consistent with their Rad6 inhibitory activities (Fig.   5C , upper panel), and provide further support for their Rad6 inhibitory function.
Discussion
The data presented here describe novel SMIs of the postreplication repair or translesion synthesis (TLS) DNA repair E2 ubiquitin conjugating enzyme Rad6B. Only one E2 enzyme SMI has been described (31), and the SMIs described here are the first that interfere with an E2 In addition to its essential function in TLS, Rad6B also regulates β-catenin levels by inducing K63-linked proteasome-insensitive ubiquitination (14) . Rad6B is also a β-catenin transcriptional target setting off a positive feedback loop between Rad6B expression and β-catenin levels in breast cancer cells (32) . SMI#8 or 9 inhibition of Rad6B ubiquitin conjugating activity results in decreased β-catenin protein levels, further demonstrating that SMIs#8 and 9 target the Rad6 ubiquitin conjugating catalytic site. The decrease in β-catenin protein levels by SMIs#8 and 9 confirms our previous observations of inhibition of β-catenin ubiquitination by Rad6B silencing (14) . attributed to SMI#9 inhibition of Rad6B-mediated K63-linked PCNA polyubiquitination (16, 17) .
The mechanism by which Rad6 SMIs inhibit cell migration is unclear, as Rad6 is not known to directly regulate cell migration. The Wnt/β-catenin pathway regulates transcription of several proteins involved in migration, including β1-integrin (33) and Snail (34) . Our previous study showed that Rad6B-mediated stabilization of β-catenin requires intact Wnt signaling as β-catenin ubiquitination was impaired in Rad6B overexpressing MDA-MB-231 subpopulations in which Wnt signaling was disrupted with a dominant negative LRP6 mutant (15) . It is possible that SMI#9 inhibition of cell migration results from inhibition of β-catenin transcriptional activity and expression of Wnt/β-catenin transcriptional targets.
Molecular modeling indicates that SMIs#8 and 9 make multiple noncovalent interactions with amino acids near the ubiquitin acceptor Cys88 (Asp90 and Gln93) and other amino acids in the pocket around the catalytic site (Thr69, Asn119, Ala122). While the Rad6A and Rad6B paralogs share all of these amino acids, no other E2 family member has more than two identical or conservative charge-preserving substitutions at these five amino acids (Fig. 6 ). This suggests that SMIs#8 and 9 would be selective for Rad6A and Rad6B. Consistent with this observation, SMI#9 did not inhibit ubiquitination of BCA2 by UbcH5B (a.k.a. UBE2D2; Fig. 2B ), which only shares Asp90 with Rad6A and Rad6B and has differently charged amino acids in place of Thr 69 (Lys) and Asn 119 (Asp). The involvement of amino acid residues predicted to interact with SMIs#8 and 9 awaits confirmation by 3-D QASAR and site-directed mutagenesis studies.
As noted above, only one other SMI of an ubiquitin E2 (CDC34a a.k.a. UBE2R1) has been described (31). This SMI acts by an allosteric mechanism different from that described for the Rad6 SMIs in this paper. The CDC34 inhibitor does not interfere with CDC34 interaction with its E1 and E3, and only weakly inhibits CDC34-ubiquitin thioester formation. Rather a residue. This prediction is consistent with our experimental data showing that SMIs#8 and 9 inhibit Rad6B activity by inhibiting Rad6B-ubiquitin thioester formation and that the decrease in ubiquitinated-histone H2A levels results from this inhibition. For both the Rad6B SMIs described here and the CDC34 inhibitors described by Ceccarelli et al (31) , it may be possible to use these SMI structures as a starting point for designing other E2 specific SMIs. 
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